- In August 2024, Tarsus Pharmaceuticals is gaining commercial momentum after the approval of Xdemvy for treating Demodex blepharitis, a prevalent but often misunderstood eyelid condition caused by Demodex mite infestations. The drug, approved in the previous summer, has started to make an impact in the market. Its availability is helping to address the unmet need for effective treatments for this chronic eye condition
- In June 2023, the FDA granted approval for Tarsus Pharmaceuticals' Xdemvy as the first FDA-approved treatment for Demodex blepharitis, a condition affecting the eyelids. This approval marks a significant milestone in the management of blepharitis. Xdemvy's introduction provides a new therapeutic option for patients suffering from this chronic eye condition
